Xiamen Amoytop Biotech Hits Day High with Strong 3.49% Intraday Surge

Xiamen Amoytop Biotech Co. has experienced a notable increase of 3.49% on August 13, 2026, reaching an intraday high of CNY 62.47. This performance stands in contrast to the China Shanghai Composite, which declined by 0.5% on the same day. Over the past week, Xiamen Amoytop has shown a robust gain of 12.55%, significantly outperforming the broader market index, which rose only 0.68%. In terms of financial health, Xiamen Amoytop reported its highest net sales at CNY 1,216.02 million and an operating profit of CNY 472.2 million. The company has maintained a strong return on equity (ROE) of 34.50%, reflecting its effective management and profitability. Despite a challenging year, where the stock has underperformed with a return of -29.47%, its profits have surged by 45.3%. The company also boasts a high dividend yield of 1.06%, indicating a commitment to returning value to shareholders. Overall, Xiamen Amoytop Biotech Co. continues to demonstrate strong operational metrics, positioning itself as a significant player in the pharmaceuticals and biotechnology sector.